Study at a glance
How was vitamin D studied in diabetes and small blood vessels?
One study compared two vitamin D3 doses in people with type 2 diabetes and peripheral neuropathy, meaning damage to nerves outside the brain and spinal cord. A separate study tested active vitamin D in blood-vessel lining cells grown in the laboratory that were exposed to high glucose. They examined different parts of a possible link between vitamin D, inflammation and small-vessel function.
What did the vitamin D3 study in people with diabetes report?
Sixty-seven people entered the 24-week study, and 62 completed it. The higher-dose group had reported improvements in selected skin blood-flow tests, some measured signs of inflammation and nerve-symptom scores. Weight and glucose control also changed. Both groups received vitamin D, treatment was known, and people were assigned to groups using a predictable even/odd method. Reporting inconsistencies further limit confidence. The study therefore could not securely show that vitamin D directly caused the vessel changes or repaired nerves.
What did active vitamin D change in cells exposed to high glucose?
Active vitamin D reduced several injury-related signals in cells exposed to high glucose. Making the cells produce more of a protein called TIPE1 opposed some of these effects, suggesting a role for that protein. This did not establish the complete mechanism or a treatment for people. The experiments had limited repetition and lacked a control needed to separate glucose-specific effects from other effects of the solution.
Do these findings establish nerve repair or prevention of diabetic complications?
A separate comparison found lower vitamin D and higher TIPE1-related measurements in people with diabetic complications, but other differences could explain the link. Neither study directly measured improved oxygen delivery to nerves or demonstrated prevention of ulcers, kidney disease or eye complications. The human study did not test TIPE1, and the cell study did not measure blood flow in an intact vessel. These findings do not establish an ideal dose or general treatment safety.
Read the full article below ↓Does vitamin D alter small-vessel dysfunction in the metabolic environment of diabetes, and which signalling pathways might connect the two? A human supplementation study reported changes in skin microcirculation and selected inflammatory markers. A separate cell study investigated injury under high glucose and a protein called TIPE1. Their findings are suggestive, but neither establishes a complete causal pathway from supplementation to prevention of diabetic complications. For the shorter account, read Vitamin D, Diabetic Microvascular Dysfunction and Metabolic Stress: Study Summary.
Why the diabetic setting changes the question
Diabetes can expose small vessels to prolonged metabolic and inflammatory stress. This makes the question more specific than whether vitamin D affects circulation in healthy volunteers. The microcirculation overview provides the anatomical context, while the studies examined here ask about functional skin responses and endothelial-cell injury. They did not directly measure whether capillaries supplied more oxygen to nerves, kidneys or the retina.
Several processes may change together: blood glucose, body weight, circulating inflammatory messengers and local vascular responses. The relationship with metabolic flexibility concerns how tissues handle changing fuel demands, but neither paper directly tested switching between glucose and fat as fuels. Metabolic improvement cannot simply be assumed to explain a vascular change without an analysis or experiment that tests that connection.
Karonova: two oral doses in people with diabetic neuropathy
Karonova and colleagues screened 98 people and enrolled 67 with type 2 diabetes and peripheral neuropathy. Eligible participants were 18 to 65 years old, had diabetes for at least five years, had glycated haemoglobin below 9%, and were on stable glucose-lowering and other relevant treatment. Glycated haemoglobin, commonly called HbA1c, reflects blood glucose exposure over preceding months. The study excluded smokers, diabetic foot disease, certain vascular and inflammatory conditions, vitamin B12 deficiency and several medicines used for pain.
The investigators allocated 34 participants to 5,000 international units of cholecalciferol, or vitamin D3, weekly and 33 to 40,000 units weekly for 24 weeks. Although described as randomised, allocation used an even/odd method. Such a predictable sequence does not provide the same protection against selection bias as concealed random allocation. Treatment was open label, and both groups received active vitamin D. The comparison therefore concerns two dosing strategies rather than supplementation against placebo.
Five people withdrew shortly after allocation: three declined further participation and two developed an upper respiratory infection. The analysed sample comprised 31 completers per group. Their median age was 56 years, and most had low vitamin D status by the paper’s definitions. The report does not provide a full intention-to-treat analysis preserving everyone originally allocated. Its public registration was first posted in May 2020, after the recorded study completion, so it cannot establish prospective outcome registration. The registry also lists 68 enrolled participants, whereas the article and flowchart report 67.
What the clinical measurements actually show
Skin microcirculation was assessed on the underside of the big toe using laser-Doppler flowmetry. After rest in a temperature-controlled room, the researchers measured basal perfusion and responses to temporary occlusion and a postural challenge. These tests describe aspects of local blood-flow regulation. They do not visualise every capillary or measure oxygen extraction by a nerve. The postural response includes a reduction in local flow, illustrating why a larger number does not always mean more blood should flow under every condition.
The higher-dose group showed reported improvements in several flow indices. Its tabulated basal perfusion value rose from 6.01 to 7.01 perfusion units, while the coefficient describing flow variability rose from 16.65% to 27.96%. The reported capillary-reserve index rose from 48.57% to 106.8%. These are instrument: and protocol-specific quantities. They must not be relabelled percentage increases in total-body circulation, capillary growth or nerve oxygen delivery.
Important reporting inconsistencies limit numerical certainty. Table 3 presents values with a plus-or-minus format but labels them medians and interquartile ranges. The prose says maximal post-occlusion flow increased in both groups, while the lower-dose values in the table fall from 9.73 to 8.97. The reserve-index definition is also insufficiently clear for reconstructing the reported percentages from aggregate values. These discrepancies are not silently corrected here. They weaken confidence in a precise effect estimate even though the higher-dose group’s reported directions are broadly favourable.
The authors used within-group Wilcoxon tests and between-group Mann: Whitney tests, with nominal significance at P < 0.05. Several outcomes and correlations were examined without a reported comprehensive multiplicity adjustment. A significant change in one group and a nonsignificant change in another is not itself proof that their changes differ. The report lacks the clarity of a prespecified, confidence-interval-based comparison of changes, so its results are best treated as exploratory evidence needing replication.
Inflammatory and metabolic changes occurred together
In the higher-dose group, median serum 25-hydroxyvitamin D rose from 16.2 to 71.6 ng/mL; in the lower-dose group it rose from 18.8 to 26.9 ng/mL. These are achieved study concentrations, not recommended targets. The higher-dose group’s median interleukin-6 fell from 2.5 to 0.6 pg/mL and interleukin-10 rose from 2.5 to 4.5 pg/mL. These are immune signalling proteins. Other measured markers, including C-reactive protein, tumour necrosis factor alpha and interleukin-1 beta, did not show significant changes.
The inflammatory result was therefore selective, not a demonstrated improvement in every aspect of inflammation. Body weight and glucose control also changed: 19 of 31 higher-dose participants lost more than 5% of body weight, and median HbA1c fell from 7.9% to 7.4%. The researchers reported stable background medicines, but the design does not establish whether vitamin D acted directly on vessels, whether changes in weight or glucose contributed, or whether other behaviour affected several outcomes together. Correlations cannot settle those alternatives.
Neuropathy scores improved in the higher-dose group, but those findings need proportionate interpretation. The median disability score fell from eight to six, while median pain on a 100-mm visual scale fell from 50 to 47 mm. A small P value does not make that three-millimetre difference a large or established clinically meaningful benefit. No nerve-conduction study, nerve-fibre biopsy or direct intraneural perfusion measurement demonstrated repair. Nor did the trial establish prevention of ulcers, kidney disease or retinal complications.
Liu: testing an endothelial response to high glucose
Liu and colleagues used cultured human umbilical vein endothelial cells at passages three to six. The cells were exposed to 35 millimolar glucose for 12 hours, followed by 100 nanomolar calcitriol for the principal 24-hour treatment protocol. Calcitriol is the active vitamin D hormone, distinct from the oral cholecalciferol used in the clinical study. The normal-glucose comparator contained 5.6 millimolar glucose. Assays also included later observation times.
The experiments examined cell viability, movement through a membrane, programmed cell death, oxidant-related fluorescence and cellular recycling structures. High glucose worsened several measures; calcitriol reduced injury signals and improved migration and viability. For example, Figure 2 shows roughly 40% positive cell-death staining with high glucose at the 24-hour assessment versus roughly 20% with calcitriol. These are approximate visual descriptions of the graph, not newly digitised estimates or percentages of rescued human vessels.
The candidate protein was tumour necrosis factor alpha-induced protein 8-like 1, abbreviated TIPE1. Its abundance rose under high glucose and fell with calcitriol. Forcing cells to produce more TIPE1 counteracted several calcitriol-associated responses, including lower oxidant signals, better migration and lower cell-death measures. This experimental perturbation supports a role for TIPE1 in that culture system. It does not show that TIPE1 is the sole mediator or that reducing it would safely treat a person with diabetes.
The link with vitamin D receptors remains partly proposed. A computer analysis identified possible receptor-binding sites in the TIPE1 gene’s promoter, the region involved in controlling gene activity. Predicted sites are not evidence of receptor occupancy in living endothelial cells. The paper did not establish the proposed promoter mechanism with receptor-binding or promoter-mutation experiments. Its pathway diagram is a hypothesis informed by the experiments and other literature, not a fully tested chain.
The study reported three independent experimental replicates and means with standard deviations. That provides limited replication, not a broad sample of adult human microvascular tissues. Umbilical-vein cells are a large-vessel model. The reported design also lacks a matched osmotic control to separate glucose-specific injury from effects of the increased solute concentration. Changes in colour-producing viability assays and fluorescence should be read as assay responses, with their own specificity limits.
Where cellular signalling and human disease remain separate
Liu’s clinical component compared 40 people with diabetes and complications with 40 without complications. Vitamin D measurements were lower and TIPE1 messenger RNA measurements higher in the complication group. Body mass index and waist circumference also differed. This was an observational comparison, with limited detail about the vitamin D analyte and no adequate adjusted causal model. It does not establish that low vitamin D caused the complications or that blood TIPE1 reflects the endothelial mechanism measured in culture.
The discussion additionally mentions improved diabetes biomarkers with insulin plus vitamin D, but the paper supplies no corresponding clinical intervention methods and results. That statement is not treated here as evidence of treatment efficacy. The supported experimental finding is narrower: active-hormone exposure changed selected high-glucose cell responses, and artificial TIPE1 overexpression opposed several of those changes. No clinical benefit should be inferred from an unexplained discussion statement.
The connection with endothelial function is biologically plausible because the cell model represents part of the vessel lining. Measurements related to endothelin and nitric oxide also touch on vascular tone, the regulation of vessel contraction and relaxation. However, the cell study did not measure an intact vessel’s diameter or flow, and the clinical trial did not measure TIPE1. The studies therefore do not directly verify each other’s mechanism.
Distinguishing vitamin D status from vitamin D effect prevents conflating blood concentrations, active-hormone exposure and tissue responses. Applying the evidence hierarchy to these two papers yields a bounded conclusion: selected clinical and cellular signals justify further controlled investigation, while reporting inconsistencies, confounding and model differences prevent a secure claim of microvascular protection. Neither study establishes an optimal dose, general treatment safety or prevention of diabetic complications.
Scientific sources
Karonova T, Stepanova A, Bystrova A, Jude EB. High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients. Nutrients. 2020;12:2518. DOI: 10.3390/nu12092518. PMID: 32825324. The complete principal paper, participant flow diagram and three tables were examined.
Liu Z, Sun H, Chen Y, He J, Zhu L, Yang B, Zhao W. High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1. Diabetology & Metabolic Syndrome. 2024;16:18. DOI: 10.1186/s13098-024-01264-5. PMID: 38216955. The complete principal paper, all six figures and clinical table were examined.
ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy. NCT04377399. First posted 6 May 2020, after the recorded study completion. This is the registration for the Karonova trial, not an independent efficacy study.
Related reading
Assessment of screening tools for diabetic sarcopenia in type 2 diabetes mellitus: evidence from a scoping review
This study aimed to map and synthesize the available evidence on screening tools for diabetic sarcopenia in patients with type 2 diabetes mellitus (T2DM), highlighting their characteristics, application contexts, and research gaps.
Original paper ↗Read more →Association Between Genetically Predicted 25‐Hydroxyvitamin D and Type 2 Diabetes Risk in South Asians: An Exploratory Two‐Sample Mendelian Randomization Study
Vitamin D deficiency and Type 2 diabetes (T2D) are highly prevalent in South Asian populations.
Original paper ↗Read more →Association between sarcopenia and the risk of diabetic cardiomyopathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study
Sarcopenia is an emerging complication of type 2 diabetes mellitus (T2DM) characterized by progressive loss of skeletal muscle mass and function.
Original paper ↗Read more →Association Between Serum 25-OH-Vitamin D and Diabetic Foot Ulcer in Patients With Type 2 Diabetes
We aimed to evaluate the association between vitamin D and diabetic foot ulcer (DFU) in patients with type 2 diabetes.
Original paper ↗Read more →Association between serum vitamin D levels and the risk of diabetic retinopathy: a meta-analysis
Inter-rater reliability was evaluated using the kappa statistic, and the kappa value was 0.89, indicating excellent agreement between the reviewers.
Original paper ↗Read more →Association Between Vitamin D Status and Diabetic Complications in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study in Hunan China
We aimed to investigate the association between vitamin D deficiency (VDD) and diabetic vascular complications, including diabetic retinopathy (DR), diabetic kidney disease (DKD), and diabetic foot ulcers (DFU).
Original paper ↗Read more →Association of serum 25-hydroxyvitamin D with urinary albumin-to-creatinine ratio and diabetic retinopathy in hospitalized patients with type 2 diabetes mellitus: a cross-sectional study
We investigated the relationships between serum 25-hydroxyvitamin D [25(OH)D] levels and urinary albumin-to-creatinine ratio (UACR) as well as diabetic retinopathy (DR) in patients with T2DM.
Original paper ↗Read more →Association of vitamin D deficiency and insufficiency with uncontrolled type 1 diabetes Mellitus among Saudi pediatric patients; a hospital-based retrospective study
In this study, we aimed to investigate the association between 25(OH)D levels and glycemic control in Saudi pediatric patients’ with T1DM in a region that is sunny year-round.
Original paper ↗Read more →Association of Vitamin D Deficiency with Diabetic Nephropathy in Type 2 Diabetes: A Hospital-Based Cross-Sectional Study
Background/Objective: Diabetic nephropathy (DN), a key microvascular complication of type 2 diabetes (T2DM), drives significant morbidity, mortality, and healthcare costs.
Original paper ↗Read more →Association of Vitamin D Deficiency with Diabetic Nephropathy in Type 2 Diabetes: A Hospital-Based Cross-Sectional Study
Background/Objective: Diabetic nephropathy (DN), a key microvascular complication of type 2 diabetes (T2DM), drives significant morbidity, mortality, and healthcare costs.
Original paper ↗Read more →Body Composition Phenotypes and Their Metabolic Associations in Treatment‐Naïve Patients With Newly Diagnosed Type 2 Diabetes: A DXA‐Based Cluster Analysis
All participants provided written informed consent.
Original paper ↗Read more →Calcitriol Supplementation Ameliorates Microvascular Endothelial Dysfunction in Vitamin D-Deficient Diabetic Rats by Upregulating the Vascular eNOS Protein Expression and Reducing Oxidative Stress
The DC group had significantly lower acetylcholine-induced relaxation and augmented endothelium-dependent contraction, with reduced eNOS expression, compared to NR rats.
Original paper ↗Read more →Determinants of incident atherosclerotic cardiovascular disease events among individuals with type 2 diabetic microvascular complications in the UK: a prospective cohort study
We included T2D participants with only microvascular complications from the UK Biobank cohort at baseline (2006 to 2010).
Original paper ↗Read more →Effect of a Brown Rice Based Vegan Diet and Conventional Diabetic Diet on Glycemic Control of Patients with Type 2 Diabetes: A 12-Week Randomized Clinical Trial
Here, we aimed to compare the effect of a vegan diet and conventional diabetic diet on glycemic control among Korean individuals.
Original paper ↗Read more →Exploratory Analysis of Type 2 Diabetes Mellitus Metabolic Phenotypes and Their Association With Vitamin D Status in Primary Care Patients
This study aimed to perform an exploratory characterisation of metabolic phenotypes in primary care patients with type 2 diabetes mellitus (T2DM), using a predefined approach and examine their association with vitamin D status.
Original paper ↗Read more →High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1
Diabetes mellitus (DM) and its associated vascular complications have become a worldwide health concern.
Original paper ↗Read more →Impact of vitamin D on glycemic control and microvascular complications in type 2 diabetes: A cross-sectional study
The mean BMI was 28.91 kg/m², and 29.1% of participants had vitamin D deficiency.
Original paper ↗Read more →Nonlinear relationship between serum ferritin and diabetic retinopathy in patients with type 2 diabetes mellitus: mediating role of neutrophil-to-albumin ratio
Participants were divided into non-DR and DR groups.
Original paper ↗Read more →Protective Role of Vitamin D Supplementation in Proliferative Diabetic Retinopathy in a Type 1 Diabetes Premenopausal Woman: A Case Report from the region of Dobrogea, Romania
We describe the clinical history, laboratory findings, and ophthalmological assessments of a 42-year-old woman from an urban area of Dobrogea, Romania.
Original paper ↗Read more →Serum 25-hydroxyvitamin D levels and prevalent diabetic retinopathy in adults with type 2 diabetes: a retrospective hospital-based matched case-control study
This study examined the adjusted association between serum 25-hydroxyvitamin D [25(OH)D] and prevalent DR.
Original paper ↗Read more →Serum 25(OH) vitamin D level and its relation to diabetic peripheral neuropathy in Egyptian patients with type 2 diabetes mellitus
Some clinical studies demonstrated a significant association between vitamin D deficiency and diabetic peripheral neuropathy (DPN).
Original paper ↗Read more →Original sources
High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients
Published in Nutrients (2020).
Publication details
Karonova T, Stepanova A, Bystrova A, Jude EB. High-Dose Vitamin D Supplementation Improves Microcirculation and Reduces Inflammation in Diabetic Neuropathy Patients. Nutrients. 2020;12:2518. DOI: 10.3390/nu12092518. PMID: 32825324. The complete principal paper, participant flow diagram and three tables were examined.
High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1
Published in Diabetology & Metabolic Syndrome (2024).
Publication details
Liu Z, Sun H, Chen Y, He J, Zhu L, Yang B, Zhao W. High glucose-induced injury in human umbilical vein endothelial cells is alleviated by vitamin D supplementation through downregulation of TIPE1. Diabetology & Metabolic Syndrome. 2024;16:18. DOI: 10.1186/s13098-024-01264-5. PMID: 38216955. The complete principal paper, all six figures and clinical table were examined.
High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy
ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy.
Publication details
ClinicalTrials.gov. High vs Low Dose Vitamin D in Patients With Diabetic Peripheral Neuropathy. NCT04377399. First posted 6 May 2020, after the recorded study completion. This is the registration for the Karonova trial, not an independent efficacy study.